Creative Medical Technology announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence with the Company’s proprietary human induced pluripotent stem cells. This iPSC clinical line is part of the Company’s iPSCelz program. “The program is designed to utilize the predictive capabilities of AI to identify damage to patients exposed to biological or chemical weapons and, based on a clinical diagnosis supported by that assessment, use the Company’s validated iPSC Inducible Pluripotent Mesenchymal Cells to treat these individuals on a patient-by-patient basis,” said Timothy Warbington, CEO of Creative Medical Technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELZ:
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
- Creative Medical CEO: ‘momentum’ towards commercialization ‘continuing to build’
- Creative Medical Technology Holdings Provides Corporate Update
- Creative Medical Technology announces development of IPSCelz program
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin